News

Pharming presents its (unaudited) financial report for the six months ended 30 June 2018.

Pharming announces the agenda for its Capital Markets Briefing to be held from 08:00 to 10:30 EST/14:00-16:30 CET on 21 June 2018 in New York, NY, and through a live webcast.

Pharming announces that at its Annual General Meeting of shareholders (AGM), held today, all proposals were approved.

Pharming presents its (unaudited) financial report for the quarter ended 31 March 2018.

On May 16th Hereditary Angioedema (HAE) patient organizations from around the world, led by HAEi (The international HAE patient organisation), come together to support the global awareness day for Hereditary Angioedema; a rare life-threatening condition.

The Dutch specialty pharmaceutical company developing innovative products for the safe, effective treatment of rare diseases and unmet medical needs, announces publication of its 2017 annual report and issues an invitation to its Annual General Meeting for all shareholders.

Today Pharming announced that it has been included in the Euronext Amsterdam SmallCap-index (AScX). On entry into the AScX, Pharming has become one of the larger index members.

Today Pharming announced that during the period of 7 to 9 March, it has issued a total of 6,315,235 new shares following the exercise of warrants representing a total of 9,174,372 shares.

Pharming presents its preliminary (unaudited) financial report for the full year ended 31 December 2017.

Today Pharming announced that the U.S. Food and Drug Administration (FDA) has accepted for review Pharming’s supplemental Biologics License Application (sBLA) for RUCONEST® [Recombinant Human C1 Esterase Inhibitor/ conestat alfa] for routine prophylaxis to prevent attacks in adult and adolescent patients with hereditary angioedema (HAE).